Metastatik kanser hastalarında tedavi seciminde nötrofil-lenfosit oranı yol gösterici olabilir: Kemoterapi veya en iyi destekleyici bakım

Amaç: Bu çalışmada nötrofil-lenfosit oranının (NLO), metastaik kanser hastaları için palyatif kemoterapiye devam etme veya en iyi destekleyici bakımı (BSC) seçme konusunda bir belirleyici olup olmadığını araştırmayı amaçladık. Yöntemler: Palyatif kemoterapi sonrası ölen metastatik kanser tanılı hastalar çalışmaya dahil edildi. Hastalar son kemoterapi rejimlerinin başlangıcı ile ölüm (DCD) arasındaki süreye göre ≤ 60 veya > 60 güne göre iki gruba ayrıldı. Nötrofil-lenfosit oranı, son kemoterapi hattı başlangıcından öncesindeki laboratuvar değerleri kullanılarak hesaplandı. ≤ 60 günlük DCD'nin belirleyici faktörleri lojistik regresyon analizi ile incelendi ve istatistiksel anlamlılık düzeyi alfa p

Neutrophil-to-lymphocyte ratio may guide the choice of treatment in metastatic cancer patients: Chemotherapy or best supportive care

Aim: We set out in this study to investigate whether the neutrophil-to-lymphocyte ratio is a predictor in deciding whether to either continue palliative chemotherapy or choose the best supportive care for advanced cancer patients.Methods: Those with advanced solid tumors who had died after palliative chemotherapy were included the study. The patients were divided into two groups based on the time between the beginning of their last chemotherapy regimen and death, at ≤ 60 or > 60 days. Neutrophil-to-lymphocyte ratio was calculated using thelaboratory values taken before the beginning of the last chemotherapy line. The determinant factors of ≤ 60-days survival were examined by logistic regression analysis, and a statistical significance level of alpha was accepted as p < 0.05.Results: The study included 404 patients, with the mean age at diagnosis of 61.7±12.0 years. The mean neutrophil-to-lymphocyte ratio was calculated as 11.3±27.1. In the univariate analysis for determining ≤ 60-days survival, breast and colorectal cancers, ECOG status, single agent chemotherapy usage, neutrophil count, lymphocyte count and neutrophil-to-lymphocyte ratio were all found to be significant factors. The cutoff value determining the ≤ 60-days DCD, was determined as NLR ≥ 3.59. In logistic regression analysis, NLR ≥ 3.59, as well as ECOG status, were found to be significant factors.Conclusion: The neutrophil-lymphocyte ratio, combined with ECOG, can predict survival in patients with solid advanced tumors and can therefore help clinicians in choosing to either administer chemotherapy to their patients or direct them to the best supportive care.

PDF

___

1.Allard P, Dionne A, Potvin D. Factors associated with length of survival among 1081 terminally ill cancer patients. J Palliat Care.1995; 11(3):20-24.
2.Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, longterm foe. Clin Cancer Res. 2009; 15(2):425-430.
3.Duman TT, Aktas G, Atak BM, Kocak MZ, Erkus E, Savli H. Neutrophil to lymphocyte ratio as an indicative of diabetic control level in type 2 diabetes mellitus. Afr Health Sci. 2019; 19(1):1602-1606.
4.Aktas G, Sit M, Dikbas O, Erkol H, Altinordu R, Erkus E, et al. Elevated neutrophil-to-lymphocyte ratio in the diagnosis of Hashimoto's thyroiditis. Rev Assoc Med Bras. 2017; 63(12):1065-1068.
5.Fang Q, Tong YW, Wang G, Zhang N, Chen WG, Li YF, et al. Neutrophil-to-lymphocyte ratio, obesity, and breast cancer risk in Chinese population. Medicine 2018; 97(30):e11692.
6.Posul E, Yilmaz B, Aktas G, Kurt M. Does neutrophil-to-lymphocyte ratio predict active ulcerative colitis? Wiener klinische Wochenschrift 2015; 127(7-8):262-265.
7.Bilgin S, Aktas G, Zahid Kocak M, Atak BM, Kurtkulagi O, Duman TT, et al. Association between novel inflammatory markers derived from hemogram indices and metabolic parameters in type 2 diabetic men. Aging Male. 2019 Jun 28:1-5. doi: 10.1080/13685538.2019.1632283
8.Sit M, Aktas G, Erkol H, Yaman S, Keyif F, Savli H. Neutrophil to Lymphocyte Ratio is Useful in Differentiation of Malign and Benign Thyroid Nodules. Puerto Rico Health Sci J. 2019; 38(1):60-63.
9.Sakin A, Sahin S, Yasar N, Demir C, Arici S, Geredeli C, et al. The Relation between Hemogram Parameters and Survival in Extensive-Stage Small Cell Lung Cancer. Oncol Res Treat. 2019; 42(10):506-515.
10.Yodying H, Matsuda A, Miyashita M, Matsumoto S, Sakurazawa N, Yamada M, et al. Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Oncologic Outcomes of Esophageal Cancer: A Systematic Review and Metaanalysis.Ann Surg Oncol. 2016; 23(2):646-654.
11.Pedrazzani C, Mantovani G, Fernandes E, Bagante F, Luca Salvagno G, Surci N, et al. Assessment of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and platelet count as predictors of long-term outcome after R0 resection for colorectal cancer. Sci Rep.2017; 7(1):1494.
12.Prodromidou A, Andreakos P, Kazakos C, Vlachos DE, Perrea D, Pergialiotis V. The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer. Inflamm Res.2017; 66(6):467-475.
13.Turri-Zanoni M, Salzano G, Lambertoni A, Giovannardi M, Karligkiotis A, Battaglia P, et al. Prognostic value of pretreatment peripheral blood markers in paranasal sinus cancer: Neutrophil-tolymphocyte and platelet-to-lymphocyte ratio. Head Neck. 2017;39(4):730-736.
14.Christakis NA, Lamont EB. Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study. BMJ. 2000; 320(7233):469-472.
15.Barbot AC, Mussault P, Ingrand P, Tourani JM. Assessing 2-month clinical prognosis in hospitalized patients with advanced solid tumors. J Clin Oncol. 2008; 26(15):2538-2543.
16.Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol. 2004; 22(2):315-321.
17.Gripp S, Moeller S, Bolke E, Schmitt G, Matuschek C, Asgari S, et al. Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol. 2007; 25(22):3313-3320.
18.Amano K, Maeda I, Shimoyama S, Shinjo T, Shirayama H, Yamada T, et al. The Accuracy of Physicians' Clinical Predictions of Survival in Patients With Advanced Cancer. J Pain Symptom Manage. 2015:50(2):139-146 e131.
19.Deng M, Ma X, Liang X, Zhu C, Wang M. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer? Oncotarget. 2017; 8(23):37200-37207.
20.Kasmann L, Bolm L, Schild SE, Janssen S, Rades D. Neutrophil-to-Lymphocyte Ratio Predicts Outcome in Limited Disease Small-cell Lung Cancer. Lung. 2017; 195(2):217-224.
21.Kang MH, Go SI, Song HN, Lee A, Kim SH, Kang JH, et al. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer. 2014; 111(3):452-460.
22.Caliskan S, Sungur M, Kaba S, Ozsoy E, Koca O, Ozturk MI. Neutrophil-to-Lymphocyte Ratio in Renal Cell Carcinoma Patients. Folia Med (Plovdiv). 2018; 60(4):553-557.
23.Zhan H, Ma JY, Jian QC. Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in melanoma patients: A meta-analysis. Clin Chim Acta. 2018; 484:136-140.
24.Szor DJ, Dias AR, Pereira MA, Ramos M, Zilberstein B, Cecconello I, et al. Prognostic Role of Neutrophil/Lymphocyte Ratio in Resected Gastric Cancer: A Systematic Review and Meta-analysis. Clinics (Sao Paulo). 2018; 73:e360.
25.Zhou Y, Wei Q, Fan J, Cheng S, Ding W, Hua Z. Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: A metaanalysis containing 8252 patients. Clin Chim Acta. 2018; 479:181-189.
26.Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2017; 19(1):2.
27.Bowen RC, Little NAB, Harmer JR, Ma J, Mirabelli LG, Roller KD, et al. Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis. Oncotarget. 2017; 8(19):32171-32189.
28.Kiriu T, Yamamoto M, Nagano T, Hazama D, Sekiya R, Katsurada M, et al. The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. PLoS One.2018; 13(2):e0193018.
29.Lau F, Downing GM, Lesperance M, Shaw J, Kuziemsky C. Use of Palliative Performance Scale in end-of-life prognostication. J Palliat Med. 2006; 9(5):1066-1075.
30.Chow E, Abdolell M, Panzarella T, Harris K, Bezjak A, Warde P, et al. Predictive model for survival in patients with advanced cancer. J Clin Oncol. 2008; 26(36):5863-5869.
31.Tredan O, Ray-Coquard I, Chvetzoff G, Rebattu P, Bajard A, Chabaud S,et al. Validation of prognostic scores for survival in cancer patients beyond first-line therapy. BMC Cancer. 2011; 11:95.